Tag Archives: SPHB

Judicious Volatility

The market has a tendency to take an extreme position, either everything is on the up or the sky is about to fall in. Well, fear is the flavour of the markets these days and that’s no bad thing given where we have come from. Still it’s annoying to hear the media full of hysterical noise on Ebola, the Middle East, Europe, Japan, Russia, oil, end of QE, deflation, etc. Hopefully, we’ll start to get some more considered arguments on what the medium term economic and earnings outlook may look like. Vitaliy Katsenelson had a nice piece on thinking through the effects of a few scenarios. Hopefully, the end of the happy-clappy market (it will likely not go easily and may well return before long) will lead to some more thoughtful pieces like that.

For now though, the smell of fear is in the air and the graph below on the ups and downs in the S&P500 show that the recent volatility is not even near correction territory (i.e. greater than 10% fall). In fact, we really haven’t had a proper correction since late 2011. As to whether this volatility will turn into a correction, I have no idea (I suspect it might take a while yet but it will get there).

click to enlargeS&P500 ups and downs

The graph below shows that the high beta stocks as measured by the Powershares high beta ETF (SPHB), as you would expect, have been hit hard here compared to the S&P500 and the low volatility ETF.

click to enlargeS&P high beta ETF

It will be interesting to see how the market develops over the coming weeks. Earnings, particularly guidance for Q4, will likely play a large part it how it plays out.

On the debate about whether historically high earnings can continue, McKinsey had an interesting article recently on the earnings and the market. The graph below from McKinsey illustrates the increased important of technology, pharma, and financials in the higher profits.

click to enlargeMckinsey Share of S&P500 profits

Spending time looking for thoughtful arguments on the impact of macro-economic, demographic and social pressure in today’s world on these sectors is a better way to understanding the medium term direction of the market. As McKinsey says “assessing the market’s current value ultimately depends on whether the profit margins are sustainable”. The rest is really just noise, best ignored or viewed from a distance.

Deflating Bubbles

The market is currently full of overdue anguish, with the air coming out of some of the frothier areas of the market notably in the biotech and internet sectors. To get an idea of the movements, I had a quick look at the S&P500 against a number of other indices such as the Powershares S&P high beta, S&P low volatility, & Nasdaq Internet ETFs plus the Nasdaq Biotech Index (SPHB, SPLV, PNQI & NBI respectively) as per the graph below.

click to enlargeS&P500 vrs SPHB SPLV NBI PNQI

One of the more amusing bubbles in the recent run-up has been that surrounding the creeping legalization of cannabis in the US. Penny stocks in the sector, as if straight out of “The Wolf of Wall Street”, have been rocketing. Some of the more dubious firms have jumped on the bandwagon by coming up with fanciful plans on exploiting cannabis markets after having tried their luck as software, oil exploration or even tanning companies! Firms such as CannaVest (CANV) and Vape Holdings (VAPE) have shown classic pump & dump penny stock rises and falls in recent months.

One stock that has rode both the biotech and the cannabis buddle is a UK firm called GW Pharmaceuticals (GWP.L) founded in 1998 to develop cannabinoid prescription medicines to meet patient needs under medical supervision. Their main product, Sativex, a treatment for moderate to severe spasticity is approved or near approval in a number of countries such as Norway, Israel, and Austria. Bulls point to approval in the US of Sativex and the potential for other cannabinoid products in areas such as cancer and diabetes to justify the current valuation of multiples of revenue for this loss making firm. GWP has risen from 50p last year to a high (forgive the pun!) of 400p in March with a fall back to 250p recently. Cannabis stocks offer the ultimate high for aging stoners, add in some biotech hype for GWP and the sky is the limit to a happy ever after fantasy……….will people ever learn!

To me, the deflating of sector bubbles is a very healthy sign of a rational market.  Whether an outbreak of rationality will last is another matter.